Application of polymerized hemoglobin in preparation of medicine for preventing and treating respiratory failure

Abstract

The invention relates to application of polymerized hemoglobin in preparation of a medicine for preventing and treating respiratory failure. The medicine disclosed by the invention is an oxygen-carrying medicine and is also a colloidal solution. Compared with whole blood or red blood cells with an oxygen-carrying function, the red blood cell has the characteristics of good rheological property, long circulation retention time, normal physiological metabolic pathway and the like, and has the advantages of no need of matching, wide working temperature range (2222 DEG C), no blood coagulation risk, stable time of 36 months and the like compared with whole blood or red blood cells with an oxygen-carrying function. Wherein the particle size of polymerized hemoglobin is only one thousandth of that of red blood cells, but the oxygen carrying capacity is as high as 729 times of that of the red blood cells, and small-dose perfusion can relieve the tissue ischemia condition and relieve inflammatory response and can reach the microcirculation tail end which cannot be reached by the red blood cells to effectively supply oxygen. A neuroprotective agent can also be added to prepare a compound medicine, so that the inflammation state of a patient with respiratory failure can be reduced, and the damage of oxygen free radicals can be reduced.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the application of polymerized hemoglobin in the preparation of medicines for preventing and treating respiratory failure. Background technique [0002] Asthma (Bronchial Asthma, BA) and chronic obstructive pulmonary disease (COPD) are common respiratory diseases characterized by progressive airflow limitation and destructive lung disease, acute lung injury (ALI ) is acute hypoxic respiratory insufficiency caused by the progression of diffuse lung lesions, while pulmonary fibrosis (PF) is a group of lung destructive diseases with different etiologies and common pathological features. One of the leading causes of death. Although BA, ALI, COPD and PF are four different diseases, there is an inseparable relationship between them. They are all relatively serious lung diseases that cause respiratory failure. Repeated attacks of BA can easily lead to lung infection, and ...

AI Technical Summary

Problems solved by technology

By inhaling oxygen, the percutaneous oxygen saturation can be maintained above 90%, and some injuries caused by hypoxia, such as pulmonary hypertension and pulmonary vascular resistance, can be improved, and the quality of life can be improved, but the time of inhaling low-flow oxygen every day is longer. Long-term, the quality of life of patients has not been effectively improved

Images